Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study ; volume:7 ; number:1 ; day:14 ; month:3 ; year:2019 ; pages:1 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (14.3.2019), 1, 12.2019
- Creator
-
Amin, Asim
Plimack, Elizabeth R.
Ernstoff, Marc S.
Lewis, Lionel D.
Bauer, Todd M.
McDermott, David F.
Carducci, Michael
Kollmannsberger, Christian
Rini, Brian I.
Heng, Daniel Y. C.
Knox, Jennifer
Voss, Martin H.
Spratlin, Jennifer
Berghorn, Elmer
Yang, Lingfeng
Hammers, Hans J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0559-3
- URN
-
urn:nbn:de:101:1-2019040714071623938788
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Amin, Asim
- Plimack, Elizabeth R.
- Ernstoff, Marc S.
- Lewis, Lionel D.
- Bauer, Todd M.
- McDermott, David F.
- Carducci, Michael
- Kollmannsberger, Christian
- Rini, Brian I.
- Heng, Daniel Y. C.
- Knox, Jennifer
- Voss, Martin H.
- Spratlin, Jennifer
- Berghorn, Elmer
- Yang, Lingfeng
- Hammers, Hans J.
- SpringerLink (Online service)
Other Objects (12)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Reversible Hypopigmentation with Pazopanib